These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [The role of raloxifene (Evista) in the treatment and prevention of postmenopausal osteoporosis].
    Author: Korsić M.
    Journal: Reumatizam; 2003; 50(2):55-7. PubMed ID: 15098379.
    Abstract:
    According to epidemiological studies in Croatia 250,000 women suffer from osteoporosis and 400,000 have osteopenia. Since osteoporosis is a disease of the elderly, and the number of older people continues to grow, it is expected that this disease and its complications (fractures) will soon become an epidemiological problem. Antiresorptive drugs include raloxifene (Evista). Raloxifene is recommended for the treatment and prevention of osteoporosis in postmenopausal women, without vasomotor symptoms. Before selection of an antiresorptive drug it is important to know not only its bone efficacy, but also other possible favorable influences on the organism. Raloxifene has positive effect on BMD (Bone Mineral Density) and bone quality. It has proven efficacy in osteoporotic fracture prevention. It is also important to emphasize the positive effect of raloxifene on the cardiovascular system and its protective effect on the breast. Raloxifene is well tolerable and is easy to take (one tablet daily, with or without food). Numerous scientific articles point to the many benefits of raloxifene. Here we would like to present the results from a randomised clinical study entitled MORE (Multiple Outcomes of Raloxifene Evaluation) conducted on 7700 postmenopausal women.
    [Abstract] [Full Text] [Related] [New Search]